Overcoming drug resistance through in silico prediction

Drug Discovery Today: Technologies

Volumn 11, Issue 1, 2014, Pages 101-107

  Carbonell, Pablo ^a,b,c   Trosset, Jean Yves ^d  

^a UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^b CNRS   (France)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d The Higher Institute of Biotechnologies of Paris   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; DRUG; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MANCOZEB;

ARTICLE; COMPUTER MODEL; DRUG DESIGN; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MUTATION; NONHUMAN; PREDICTION; CHEMICAL STRUCTURE; COMPUTER SIMULATION; SYSTEMS BIOLOGY;

COMPUTER SIMULATION; DRUG RESISTANCE; MOLECULAR STRUCTURE; SYSTEMS BIOLOGY;

EID: 84899949915     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2014.03.012     Document Type: Review

References (70)

1. D.P. Gnanadhas, S.A. Marathe, and D. Chakravortty Cross-resistance mechanisms and assessment Expert Opin Investig Drugs 22 2013 191 206
2. Y. Zhang, and W.W. Yew Mechanisms of drug resistance in Mycobacterium tuberculosis Int J Tuberc Lung Dis 13 2009 1320 1330
3. R. Simon, and S. Roychowdhury Implementing personalized cancer genomics in clinical trials Nat Rev Drug Discov 12 2013 358 369
4. Y. Zhao, and D. Zeng Recent development on statistical methods for personalized medicine discovery Front Med 7 2013 102 110
5. D.A. Chan, and A.J. Giaccia Harnessing synthetic lethal interactions in anticancer drug discovery Nat Rev Drug Discov 10 2011 351 364
6. L. Liu, S. May, D.D. Richman, F.M. Hecht, M. Markowitz, and E.S. Daar et al. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance AIDS 22 2008 835 839
7. D. Frentz, C.A.B. Boucher, M. Assel, A. Luca, M. De Fabbiani, and A. Vandamme et al. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time PLoS ONE 5 2010 1 9
8. E. Jenwitheesuk, K. Wang, J.E. Mittler, and R. Samudrala PIRSpred: a web server for reliable HIV-1 protein-inhibitor resistance/susceptibility prediction Trends Microbiol 13 2005 150 151
9. H. Borchani, C. Bielza, C. Toro, and P. Larrañaga Predicting human immunodeficiency virus inhibitors using multi-dimensional Bayesian network classifiers Artif Intell Med 57 2013 219 229
10. S. Drǎghici, and R.B. Potter Predicting HIV drug resistance with neural networks Bioinformatics 19 2003 98 107
11. E. Hazai, I. Hazai, I. Ragueneau-majlessi, S.P. Chung, Z. Bikadi, and Q. Mao Predicting substrates of the human breast cancer resistance protein using a support vector machine method Bioinformatics 14 2013 2 7
12. D. Schuster 3D pharmacophores as tools for activity profiling Drug Discov Today Technol 7 2010 e203 e270
13. Y. Mao Dynamical basis for drug resistance of HIV-1 protease BMC Struct Biol 11 2011 1 9
14. R. Barouch-Bentov, and K. Sauer Mechanisms of drug resistance in kinases Expert Opin Investig Drugs 20 2011 153 208
15. K.M. Frey, I. Georgiev, B.R. Donald, and A.C. Anderson Predicting resistance mutations using protein design algorithms Proc Natl Acad Sci U S A 107 2010 13707 13712
16. J.V. Ribeiro, Cerqueira NMFSA, I.S. Moreira, P.A. Fernandes, and M.J. Ramos CompASM: an Amber-VMD alanine scanning mutagenesis plug-in Theor Chem Acc 131 2012 1271 1277
17. G-F. Hao, G-F. Yang, and C-G. Zhan Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors J Phys Chem B 114 2010 9663 9676
18. C. Mcmartin A geometry force field which converts low-resolution X-ray models to structures with properties found at ultra high resolution Protein Sci 21 2012 75 83
19. J.A. Bikker, N. Brooijmans, A. Wissner, and T.S. Mansour Kinase domain mutations in cancer: implications for small molecule drug design strategies J Med Chem 52 2009 1493 1509
20. H. Daub, K. Specht, and A. Ullrich Strategies to overcome resistance to targeted protein kinase inhibitors Nat Rev Drug Discov 3 2004 1000 1010
21. M. Pierotti, E. Tamborini, T. Negri, S. Pricl, and S. Pilotti Targeted therapy in GIST: in silico modeling for prediction of resistance Nat Rev Clin Oncol 8 2011 161 170
22. F. Jin, T. Hazbun, G.A. Michaud, M. Salcius, P.F. Predki, and S. Fields et al. A pooling-deconvolution strategy for biological network elucidation Nat Methods 3 2006 183 189
23. J-Y. Trosset, and P. Carbonell Synergistic synthetic biology: units in concert Front Bioeng Biotechnol 1 2013 1 11
24. J.S. Logue, and D.K. Morrison Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy Genes Dev 26 2012 641 650
25. E. Klipp, R.C. Wade, and U. Kummer Biochemical network-based drug-target prediction Curr Opin Biotechnol 21 2010 511 516
26. H. Kitano A robustness-based approach to systems-oriented drug design Nat Rev Drug Discov 6 2007 202 210
27. A. Pujol, R. Mosca, J. Farrés, and P. Aloy Unveiling the role of network and systems biology in drug discovery Trends Pharmacol Sci 31 2010 115 123
28. P. Csermely, T. Korcsmaros, H.J.M. Kiss, G. London, and R. Nussinov Structure and dynamics of molecular networks: a novel paradigm of drug discovery. A comprehensive review Pharmacol Ther 138 2012 333 408
29. M.J. Keiser, V. Setola, J.J. Irwin, C. Laggner, A.I. Abbas, and S.J. Hufeisen et al. Predicting new molecular targets for known drugs Nature 462 2009 175 181
30. M.A. YIldIrIm, K. Goh, M.E. Cusick, A. Barabási, and M. Vidal Drug - target network Nat Biotechnol 25 2007 1119 1126
31. I.M. Overton, S. Graham, K.A. Gould, J. Hinds, C.H. Botting, and S. Shirran et al. Global network analysis of drug tolerance, mode of action and virulence in methicillin-resistant S. aureus BMC Syst Biol 5 2011 68 84
32. O. Sahin, H. Fröhlich, C. Löbke, U. Korf, S. Burmester, and M. Majety et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance BMC Syst Biol 3 2009 1 20
33. P.J. Dias, C.P. Costa, I. Sá-correia, and M.C. Teixeira Using systems biology approaches to study a multidrug resistance network Bioieng ENBENG 12 2011 68 84
34. R. Gehring, P. Schumm, M. Youssef, and C. Scoglio A network-based approach for resistance transmission in bacterial populations J Theor Biol 262 2010 97 106
35. J.L. Martínez, F. Baquero, and D.I. Andersson Predicting antibiotic resistance Nat Rev Microbiol 5 2007 958 965
36. J.D. Orth, I. Thiele, and B.O. Palsson What is flux balance analysis? Nat Biotechnol 28 2010 245 248
37. J.D. Trawick, and C.H. Schilling Use of constraint-based modeling for the prediction and validation of antimicrobial targets Biochem Pharmacol 71 2006 1026 1035
38. L. Nguyen, and C.J. Thompson Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm Trends Microbiol 14 2006 304 312
39. D.J.V. Beste, and J. McFadden System-level strategies for studying the metabolism of Mycobacterium tuberculosis Mol Biosyst 6 2010 2363 2372
40. K. Raman, and N. Chandra Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance BMC Microbiol 8 2008 234 247
41. N.C. Duarte, S.A. Becker, N. Jamshidi, I. Thiele, M.L. Mo, and T.D. Vo et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data Proc Natl Acad Sci U S A 104 2007 1777 1782
42. H.U. Kim, T.Y. Kim, and S.Y. Lee Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE Mol Biosyst 6 2010 339 348
43. L.L. Silver Multi-targeting by monotherapeutic antibacterials Nat Rev Drug Discov 6 2007 41 55
44. A. Raghunathan, J. Reed, S. Shin, B. Palsson, and S. Daefler Constraint-based analysis of metabolic capacity of Salmonella typhimurium during host-pathogen interaction BMC Syst Biol 3 2009 38 54
45. A. Ramos-Montoya, W.N. Lee, S. Bassilian, S. Lim, R.V. Trebukhina, and M.V. Kazhyna et al. Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer Int J Cancer 119 2006 2733 2741
46. I. Thiele, N. Swainston, R.M.T. Fleming, A. Hoppe, S. Sahoo, and M.K. Aurich et al. A community-driven global reconstruction of human metabolism Nat Biotechnol 31 2013 419 425
47. R.H. Blair, D.L. Trichler, and D.P. Gaille Mathematical and statistical modeling in cancer systems biology Front Physiol 3 2012 227 235
48. O. Resendis-Antonio, A. Checa, and S. Encarnación Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect PLoS ONE 5 2010 1 11
49. H.J. Huber, H. Dussmann, S.M. Kilbride, M. Rehm, and J.H.M. Prehn Glucose metabolism determines resistance of cancer cells to bioenergetic crisis after cytochrome-c release Mol Syst Biol 7 2011 470 485
50. G. Hao, G. Yang, and C. Zhan Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem Drug Discov Today 17 2012 1121 1126
51. Y. Wang, C. Tang, E. Wang, and J. Wang Exploration of multi-state conformational dynamics and underlying global functional landscape of maltose binding protein PLoS Comput Biol 8 2012 e1002421 e1002471
52. O. Doppelt-Azeroual, F. Moriaud, S.A. Adcock, and F. Delfaud A review of MED-SuMo applications Infect Disord Drug Targets 9 2009 344 357
53. J.A. Mccubrey, L.S. Steelman, W.H. Chappell, L. Stephen, R.A. Franklin, and G. Montalto et al. Ras/Raf/MEK/ERK PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance Oncotarget 3 2012 1068 1111
54. H. Zahreddine, and K.L.B. Borden Mechanisms and insights into drug resistance in cancer Front Pharmacol 4 2013 1 8
55. A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, and D. Zecchin et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
56. H.A. Burris Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway Cancer Chemother Pharmacol 71 2013 829 842
57. M. Seltzer, B. Bennett, A. Joshi, P. Gao, A. Thomas, and D. Ferraris et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH Cancer Res 70 2010 8981 8987
58. M. Yuneva, N. Zamboni, P. Oefner, R. Sachidanandam, and Y. Lazebnik Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells J Cell Biol 178 2007 93 105
59. A. Zinovyev, I. Kuperstein, E. Barillot, and W-D. Heyer Synthetic lethality between gene defects affecting a single non-essential molecular pathway with reversible steps PLoS Comput Biol 9 2013 e1003016
60. H.U. Kim, S.B. Sohn, and S.Y. Lee Metabolic network modeling and simulation for drug targeting and discovery Biotechnol J 7 2012 330 342
61. G. Plata, T-L. Hsiao, K.L. Olszewski, M. Llinás, and D. Vitkup Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network Mol Syst Biol 6 2010 1 15
62. S. Joon, E. Seo, and Y. Cho Proposal for a new therapy for drug-resistant malaria using Plasmodium synthetic lethality inference Int J Parasitol 3 2013 119 128
63. A. Metris, M. Reuter, D.J.H. Gaskin, J. Baranyi, and A.H.M. van Vliet In vivo and in silico determination of essential genes of Campylobacter jejuni BMC Genomics 12 2011 535 549
64. M.P. Brynildsen, J.A. Winkler, C.S. Spina, I.C. MacDonald, and J.J. Collins Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production Nat Biotechnol 31 2013 160 165
65. G. Sigurdsson, R.M.T. Fleming, A. Heinken, and I. Thiele A systems biology approach to drug targets in Pseudomonas aeruginosa biofilm PLoS ONE 7 2012 e34337
66. Z. Xu, X. Fang, T.K. Wood, and Z.J. Huang A systems-level approach for investigating Pseudomonas aeruginosa biofilm formation PLoS ONE 8 2013 e57050
67. A-G. Planson, P. Carbonell, I. Grigoras, and J-L. Faulon Engineering antibiotic production and overcoming bacterial resistance Biotechnol J 6 2011 812 825
68. O. Folger, L. Jerby, C. Frezza, E. Gottlieb, E. Ruppin, and T. Shlomi Predicting selective drug targets in cancer through metabolic networks Mol Syst Biol 7 2011 1 10
69. L. Jerby, and E. Ruppin Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling Clin Cancer Res 18 2012 5572 5584
70. A. Thomas, S. Rahmanian, A. Bordbar, B.∅. Palsson, N. Jamshidi, and A. Thomas et al. Network reconstruction of platelet metabolism identifies metabolic signature for aspirin resistance Sci Rep 4 2014 1 10